Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Autologous CXCR2-modified CD70 CAR-T cells |
Synonyms | |
Therapy Description |
Autologous CXCR2 modified CD70 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD70 and expressing the IL-8 receptor CXCR2, which may relieve tumor immunosuppression and inhibit tumor growth (PMID: 31488817). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Autologous CXCR2-modified CD70 CAR-T cells | autologous 8R-70CAR T-cells|autologous IL-8RB-modified CD70-CAR T-cells | Autologous CXCR2-modified CD70 CAR-T cells are autologous T-lymphocytes engineered to express the IL-8 receptor CXCR2 and a chimeric antigen receptor (CAR) targeting CD70, which may increase antitumor immune response and inhibit tumor growth (PMID: 31488817). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05353530 | Phase I | Autologous CXCR2-modified CD70 CAR-T cells | Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) (IMPACT) | Recruiting | USA | 0 |